Boryung Pharmaceutical Aims for Record-Breaking Sales in 2024

Q: How long will it take to read this news story?

The story "Boryung Pharmaceutical Aims for Record-Breaking Sales in 2024" has 559 words across 24 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Boryung Pharmaceutical Aims for Record-Breaking Sales in 2024" was covered 1 months ago by Korea Economic Daily, a news publisher based in South Korea.

Q: How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news. The outlet is headquartered in South Korea and publishes an average of 5 news stories per day. It's most recent story was published 19 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #20477799</li><li>URL: https://beamstart.com/news/drug-maker-boryung-targets-its-17109157296859</li></ul>

Korea Economic Daily Logo Korea Economic Daily 1 mo ago

Boryung Pharmaceutical Aims for Record-Breaking Sales in 2024 - Korea Economic Daily

Quick Summary:

It added the reflux esophagitis treatment to its portfolio as its new distributor.“We will open the era of 1 trillion won in sales this year, taking a leap forward to become a leading pharmaceutical company,” Boryung’s Chief Executive Daniel Chang told The Korea Economic Daily in an interview.“We will focus all our capabilities on strengthening the competitiveness of our prescription drugs for chronic diseases such as high blood pressure, dyslipidemia, cancer and diabetes,” said the CEO, also known as his Korean name Chang Doo-hyun.

Boryung Corp., formerly Boryung Pharmaceutical Co., aims to join the 1 trillion won ($748 million) sales club this year, driven by new chronic disease drugs and product diversification, with an aim of becoming the country’s No.1 pharmaceutical company by 2032, its chief executive said on Tuesday.

By 2026, Boryung targets 200 billion won in sales of the Kanarb line.It has cemented its No.1 position as the most-prescription drug maker in terms of sales in Korea among the domestically-developed novel treatments.